Eye scans detect Parkinson’s years before symptoms surface – Health

Summary: A new study has identified markers in eye scans that can detect the presence of Parkinson’s disease an average of seven years before clinical presentation. The study, the largest of its kind, used artificial intelligence to analyze retinal imaging, which reveals these early indicators of Parkinson’s.

The innovative field of “oculomics” has previously revealed symptoms of various neurodegenerative conditions through eye scans. This development brings hope for early intervention and prevention of the debilitating disease.

Key Information:

  1. Retinal imaging detects markers of Parkinson’s disease seven years before clinical symptoms.
  2. The study used AI to analyze the AlzEye dataset and confirmed results with the UK Biobank database.
  3. This “oculomics” technique has previously identified early signs of Alzheimer’s, multiple sclerosis and schizophrenia.

Source: UCL

Markers that indicate the presence of Parkinson’s disease in patients an average of seven years before clinical presentation have been identified by a research team at UCL and Moorfields Eye Hospital.

This is the first time anyone has shown these results years before diagnosis, and the findings are made possible by the largest study to date on retinal imaging in Parkinson’s disease.

https://pubads.g.doubleclick.net/gampad/ads?sz=320x480|336x280|120x60|120x90|1x1|400x300|125x125|250x250|320x50|468x60&iu=/22912810984/POSTAD&ciu_szs='fluid',125x125,250x250&env=vp&impl=s&gdfp_req=1&output=vast&unviewed_position_start=1&url=[referrer_url]&description_url=[description_url]&correlator=[timestamp]
It was also found that a reduced thickness of these layers was associated with an increased risk of developing Parkinson’s disease, beyond that provided by other factors or comorbidities. Credit: Neuroscience News

The study, published today neurology, Artificial Intelligence (AI) Detects Parkinson’s Markers in Eye Scans

The analysis of the AlzEye dataset was repeated using the wider UK Biobank database (healthy volunteers), which replicated the findings.

The use of these two large, robust datasets enabled the team to identify these subtle markers, despite the relatively low prevalence of Parkinson’s disease (0.1-0.2% of the population). Generation of the AlzEye dataset was enabled by Insight, the world’s largest database of retinal images and associated clinical data.

An emerging and exciting field of research formerly referred to as “oculomics” uses data from eye scans to reveal symptoms of other neurodegenerative conditions, including Alzheimer’s, multiple sclerosis and, more recently, schizophrenia.

Eye scans and eye data have also been able to reveal trends in hypertension; Cardiovascular disease including stroke; and diabetes.

Doctors have long known that the eyes can act as a ‘window’ to the rest of the body, providing direct insight into many aspects of our health.

High-resolution images of the retina are now a routine part of eye care – in particular, a type of 3D scan known as ‘optical coherence tomography’ (OCT), which is widely used in eye clinics and high-street opticians. In less than a minute, an OCT scan creates an incredible cross-section of the retina (the back of the eye) – down to a thousandth of a millimetre.

These images are extremely useful for monitoring eye health, but their value is even greater, as retinal scans are the only non-invasive way to see cell layers below the surface of the skin.

In recent years, researchers have begun using powerful computers to accurately analyze large numbers of OCT and other eye images, which would take a human.

Using a type of AI known as ‘machine learning’, computers are now able to uncover hidden information about the entire body just from these images. Oculomics is all about harnessing this new potential.

Lead author Dr Siegfried Wagner (UCL Institute of Ophthalmology and Moorfields Eye Hospital), who is the principal investigator of several other Alzheimer’s studies, said: “I continue to be amazed by what we can discover with eye scans. Although we are not yet ready to predict whether a person will develop Parkinson’s disease, we hope that this method may soon become a pre-screening tool for those at risk of the disease.

“Finding the signs of several diseases before symptoms appear means that, in the future, people may have time to make lifestyle changes to prevent the onset of certain conditions, and physicians may be able to delay the onset and impact of life-changing neurodegenerative disorders.”

The work involved collaboration between the NIHR (National Institute of Health and Social Care) Biomedical Research Center Moorfields Eye Hospital, University Hospital Birmingham, Great Ormond Street Hospital (GOSH), Oxford University Hospitals, University College Hospital London and UCL Great Ormond. Street Institute of Child Health. The scope and quality of research is maximized through this exceptional NHS research partnership.

Professor Alastair Denniston, Consultant Ophthalmologist at University Hospitals Birmingham, Professor at the University of Birmingham and part of the NIHR Moorfields BRC, said: “This work demonstrates the potential of eye data, used by technology to pick up symptoms and changes that are too subtle for humans to see. . We can now detect very early signs of Parkinson’s, opening new possibilities for treatment.”

Miss Louisa Wickham, Medical Director at Moorfields, explained: “Increasing imaging across the wider population will have a huge impact on public health in the future and will ultimately lead to predictive analytics. OCT scans are more scalable, non-invasive, less expensive and faster than brain scans for this purpose.”

More technical and background information on the study

Parkinson’s disease is a progressive neurological condition characterized by depletion of dopamine, and postmortem examinations of patients with Parkinson’s disease have found differences in the retinal INL (inner nuclear layer).

Previous studies using OCT scans have found possible morphologic abnormalities associated with the disease, but there are inconsistencies.

This study confirmed previous reports of a significantly thinner GCIPL (ganglion cell-inner plexiform layer), while finding a thinner INL for the first time. It was also found that a reduced thickness of these layers was associated with an increased risk of developing Parkinson’s disease, beyond that provided by other factors or comorbidities.

Future studies are needed to determine whether the progression of GCIPL atrophy is driven by brain changes in Parkinson’s disease or whether INL thinning precedes GCIPL atrophy. This may help explain the discovery process and determine whether retinal imaging can support the diagnosis, prognosis, and complex management of patients with Parkinson’s disease.

The study lacked detailed clinical information about Parkinson’s disease status (exact date of diagnosis, type of treatment, and current therapy) among patients, which may have related retinal changes to disease duration or progression.

This visual neuroscience and Parkinson’s disease research news

Author: Chris Lane
Source: UCL
Contact: Chris Lane – UCL
Image: Image credited to Neuroscience News

Original Research: The result will be displayed Neurology

Leave a Comment

Java Burn – Shocking Customer Side Effects Update Fast Lean Pro Reviews (Hidden Truth Exposed!) Real Weight Loss Or Cheap Customer Results? A perfect scientific ingredient for weight loss GlucoTrust Reviews Disclosed Beware NoBody Tells You This Alpilean Weight Loss Formula
Java Burn – Shocking Customer Side Effects Update Fast Lean Pro Reviews (Hidden Truth Exposed!) Real Weight Loss Or Cheap Customer Results? A perfect scientific ingredient for weight loss GlucoTrust Reviews Disclosed Beware NoBody Tells You This Alpilean Weight Loss Formula